| Literature DB >> 32208935 |
Dong-Jie Li1,2,3,4, Zhang-Cheng Liao5, Xiao-Bo Zhang3,4, Yu-Xin Tang6, Xiong-Bing Zu5, Long Wang5, Yang Yang7, Hua Peng3,4, Xiu-Cheng Li5, Zheng-Yan Tang4,5,8, Xiao-Ping Chen1,2,4.
Abstract
Entities:
Keywords: Erectile dysfunction; cardiologist; cardiovascular disease; education; phosphodiesterase type V inhibitor; postdoctoral degree; urologist
Mesh:
Year: 2020 PMID: 32208935 PMCID: PMC7370811 DOI: 10.1177/0300060519894187
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Characteristics of participants based on their understanding of the association between ED and CVD.
ED and CVD | |||
|---|---|---|---|
| Characteristics | Closely associated(n = 552) | Not closely associated (n = 99) |
|
| Age, years | 34.28 ± 8.82 | 32.40 ± 8.87 | 0.520 |
| Male sex | 354 (64.1%) | 59 (59.6%) | 0.388 |
| Years of practice | 9.60 ± 8.66 | 7.56 ± 7.56 | 0.028 |
| Educational background | |||
| College/junior college degree | 295 (53.4%) | 60 (60.6%) | 0.187 |
| Postgraduate degree | 162 (29.3%) | 30 (30.3%) | 0.848 |
| ≥Doctoral degree | 95 (17.2%) | 9 (9.1%) | 0.042 |
| Professional title | |||
| Primary title | 274 (49.6%) | 63 (63.6%) | 0.010 |
| Intermediate title | 178 (32.2%) | 25 (35.3%) | 0.167 |
| Senior title | 100 (18.1%) | 11 (11.1%) | 0.088 |
| Level of hospital | |||
| Community hospital | 91 (16.5%) | 21 (21.2%) | 0.251 |
| Secondary hospital | 164 (29.7%) | 35 (35.4%) | 0.262 |
| Tertiary hospital | 297 (53.8%) | 43 (43.4%) | 0.057 |
Values are mean ± standard deviation or n (%).ED: erectile dysfunction, CVD: cardiovascular disease.
Comparison of perceptions between cardiologists and urologists.
| Perceptions | Cardiologists (n = 245) | Urologists (n = 406) |
|
|---|---|---|---|
| ED is regarded as a natural aging process rather than a disease | 149 (60.8) | 197 (48.5) | 0.002 |
| ED is closely associated with CVD | 210 (85.7) | 342 (84.2) | 0.611 |
| Association of severity of ED and CVD | 130 (53.1) | 291 (71.2) | <0.001 |
| ED and CVD are managed together/systemically | 66 (26.9) | 358 (88.2) | <0.001 |
| Effect of PDE5 inhibitor administration on patients with CVD | |||
| Benefit | 48 (19.6) | 103 (25.4) | 0.910 |
| Harm | 148 (60.4) | 192 (47.3) | 0.001 |
| No effect | 49 (20.0) | 111 (27.3) | 0.035 |
| Main concern about PDE5 inhibitor administration in patients with CVD | |||
| No concern | 54 (22.0) | 84 (20.7) | 0.683 |
| Safety | 168 (68.6) | 211 (52.0) | <0.001 |
| Validity | 27 (6.9) | 72 (17.7) | 0.021 |
| Other | 6 (2.4) | 39 (9.6) | <0.001 |
| Consideration of ED and CVD during the follow-up visit | 70 (28.6) | 371 (91.4) | <0.001 |
Values are n (%).ED: erectile dysfunction, CVD: cardiovascular disease, PDE5: phosphodiesterase type V.
Figure 1.(a) The most important association between ED and CVD according to cardiologists’ and urologists’ responses to question 9 in the questionnaire (“What is the most important association between ED and CVD?”). **P < 0.001. (b) Major clinical significance of the association of ED and CVD according to cardiologists’ and urologists’ responses to question 10 in the questionnaire (“What is the major instructive clinical significance of ED or CVD taking into account the association between these two disorders?”). **P < 0.001.
Sex differences in the perception of the association between ED and CVD.
| Perceptions | Male sex (n = 413) | Female sex (n = 238) |
|
|---|---|---|---|
| ED is regarded as a natural aging process | 202 (48.9) | 144 (60.5) | 0.004 |
| ED is closely associated with CVD | 354 (85.7) | 198 (83.2) | 0.388 |
| Association between the severity of ED and CVD | 281 (68.0) | 140 (58.8) | 0.018 |
| ED and CVD are managed together/systematically | 320 (77.5) | 104 (43.7) | <0.001 |
| Effect of PDE5 inhibitor administration | |||
| Benefit | 98 (23.7%) | 53 (22.3) | 0.671 |
| Harm | 205 (49.6) | 135 (56.7) | 0.081 |
| No effect | 110 (26.6) | 50 (21.0) | 0.108 |
| Main concern about PDE5 inhibitor administration in patients with CVD | |||
| No concern | 87 (21.1) | 51 (21.4) | 0.409 |
| Safety | 236 (57.1) | 143 (60.1) | 0.464 |
| Validity | 64 (15.5) | 25 (10.5) | 0.074 |
| Other | 26 (6.3) | 19 (8.0) | 0.414 |
| Consideration of both ED and CVD during the follow-up visit | 339 (82.1) | 102 (42.9) | <0.001 |
Values are n (%).ED: erectile dysfunction, CVD: cardiovascular disease, PDE5: phosphodiesterase type V.
Factors associated with participants’ systematic management of patients with ED and CVD.
| Characteristics | OR | 95% CI | |
|---|---|---|---|
| Department (urology vs cardiology) | 20.228 | 13.385–30.566 | <0.001 |
| Age (≥40 vs <40) | 0.901 | 0.608–1.335 | 0.602 |
| sex (men vs women) | 6.091 | 4.274–8.680 | <0.001 |
| Professional years (≥10 vs <10) | 2.000 | 1.417–2.822 | <0.001 |
| Educational background (<doctoral degree vs ≥doctoral degree) | 1.936 | 1.266–2.959 | 0.002 |
| Professional title (≥senior title vs< senior title) | 1.086 | 0.705–1.673 | 0.709 |
| Level of hospital (≤tertiary hospital vs tertiary hospital) | 1.657 | 0.197–2.292 | 0.002 |
| ED is regarded as a natural aging process rather than a disease (yes vs no) | 0.775 | 0.560–1.072 | 0.123 |
| ED is closely associated with CVDs (yes vs no) | 0.923 | 0.587–1.451 | 0.728 |
| There is an association between the severity of ED and CVD (yes vs no) | 1.943 | 1.391–2.712 | <0.001 |
| Effect of PDE5 inhibitor administration on patients with CVD (uninfluential vs not influential) | 0.691 | 0.469–1.019 | 0.061 |
| Concern about PDE5 inhibitor administration in patients with CVD (concerned vs not concerned) | 1.656 | 1.129–2.430 | 0.010 |
OR: odds ratio, CI: confidence interval, ED: erectile dysfunction, CVD: cardiovascular disease, PDE5: phosphodiesterase type V.